ONCO - Rasio utang marang kapitalisasi buku Onconetix Inc

Growth for Onconetix, Inc. (ONCO) is driven by the expansion of the drug Entadfi and new B2B contracts. The business relies on the implementation of diagnostic systems in Europe and the US. The history of the net debt-to-equity ratio shows that the metric level is 0.01. This sector is crisis-resistant, as prostate therapy and oncology remain priorities regardless of macroeconomic fluctuations.

This indicator determines the degree of business financial autonomy through the ratio of total liabilities to equity. The metric assesses the resilience of the financing structure to market shocks. By analyzing the history of debt-to-equity ratios, an investor identifies the balance between debt load and growth potential. For Onconetix, Inc. (ONCO), a low debt level is critical during the commercialization of cancer therapy drugs, ensuring the company's survival until the completion of clinical trials.